1 Riese DJ 2nd, Stern DF (1998) Specificity within the EGF family/ErbB re- ceptor family signaling network. Bioessays 20: 41-48.

2 Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.

3 Riese DJ 2nd, Gallo RM, Settleman J (2007) Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduc- tion and tumorigenesis. Bioessays 29: 558-565.

4 Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd, et al. (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 122: 1-8.

5 Elenius K, Corfas G, Paul S, Choi CJ, Rio C, et al. (1997) A novel juxtam- embrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribu- tion and differential processing in response to phorbol ester. J Biol Chem 272: 26761-26768.

6Gilbertson R, Hernan R, Pietsch T, Pinto L, Scotting P, et al. (2001) Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 31: 288-294.

7 Cheng QC, Tikhomirov O, Zhou W, Carpenter G (2003) Ectodomain cleav- age of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 278: 38421-38427.

8 Ni CY, Murphy MP, Golde TE, Carpenter G (2001) gamma -Secretase cleav- age and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181.

9 Rio C, Buxbaum JD, Peschon JJ, Corfas G (2000) Tumor necrosis factor- alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275: 10379-10387.

10 Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS (2004) The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by function- ing as a STAT5A nuclear chaperone. J Cell Biol 167: 469-478.

11 Edwards DP (2000) The role of coactivators and corepressors in the bi- ology and mechanism of action of steroid hormone receptors. J Mammary Gland Biol Neoplasia 5: 307-324.

12 Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736.

13 Savkur RS, Burris TP (2004) The coactivator LXXLL nuclear receptor rec- ognition motif. J Pept Res 63: 207-212.

14 Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, et al. (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66: 6412-6420.

15 Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278: 33334-33341.

16 Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, et al. (2004) Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294: 469-479.

17 Hung AY, Sheng M (2002) PDZ domains: structural modules for protein complex assembly. J Biol Chem 277: 5699-5702.

18 Ni CY, Yuan H, Carpenter G (2003) Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage. J Biol Chem 278: 4561-4565.

19 Arteaga CL (2006) EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 9: 421-423.

20 Arteaga CL, Moulder SL, Yakes FM (2002) HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29: 4-10.

21 Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184.

22 Ji H, Sharpless NE, Wong KK (2006) EGFR targeted therapy: View from biological standpoint. Cell Cycle 5: 2072-2076.

23 Roskoski R Jr (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1-11.

24 Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF (1996) Type 1 recep- tor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148: 549-558.

25 Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, et al. (2005) Ab- sence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163-2168.

26 deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL (2000) Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87: 487-498.

27 Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, et al. (2005) Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast can- cer cells. Cancer Res 65:1384-1393.

28 Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, et al. (2000) c-erbB-4 protein expression in human breast cancer. Br J Cancer 82(6): 1163-1170.

29 Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, et al. (1997) Tissue ex- pression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3: 21-30.

30 Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, et al. (2004) Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91: 2034-2041.

31 Robinson D, He F, Pretlow T, Kung HJ (1996) A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci U S A 93: 5958-5962.

32 Srinivasan R, Poulsom R, Hurst HC, Gullick WJ (1998)Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol. 185: 236-245.

33 Thybusch-Bernhardt A, Beckmann S, Juhl H (2001) Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 corre- lates with a favourable tumor stage.Int J Surg Investig 2: 393-400.

34 Vidal GA, Clark DE, Marrero L, Jones FE (2007) A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-kill- ing activities.Oncogene 26: 462-466.

35 Vidal GA, Naresh A, Marrero L, Jones FE (2005) Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 280: 19777-19783.

36 Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, et al. (2008) Role of ErbB4 in breast cancer. Journal of Mammary Gland Biology & Neoplasia 13: 259-268.

37 Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS (2008) ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.J Mammary Gland Biol Neoplasia 13: 235-246.

38 Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, et al. (2011) Function of ERBB4 is determined by alternative splicing. Cell Cycle 10: 2647-2657.

39 Gordon-Thomson C, Jones J, Mason RS, Moore GP (2005) ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 15: 21-28.

40 Mill CP, Gettinger KL, Riese DJ 2nd (2011) Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological re- sponses in human pancreatic tumor cell lines. Exp Cell Res 317:b392-404.

41 Penington DJ, Bryant I, Riese DJ 2nd (2002) Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 13: 247-256.

42 Pitfield SE, Bryant I, Penington DJ, Park G, Riese DJ 2nd (2006) Phospho- rylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.Oncol Res 16: 179-293.

43 Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, et al. (2003) A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 192: 67-74.

44 Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ (2006) Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun 349: 372-382.

45 Jones FE(2008) HER4 intracellular domain (4ICD) activity in the devel- oping mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 13: 247-258.

46 Naresh A, Long W, Vidal GA, Wimley WC, Marrero L et al. (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66: 6412-6420.

47 Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE, et al. (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395.

48 Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, et al. (2010) The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer 9: 150.

49 Thor AD, Edgerton SM, Jones FE (2009) Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 175: 1802-1809.

50 Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, et al. (2006) Coreg- ulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66: 7991-7998.

51 Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ 2nd, et al. (1991) Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol 65: 7078-7083.

52 Riese DJ 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF (1995) The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770-5776.

53 Kelekar A, Thompson CB (1998) Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 8: 324-330.

54 Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, et al. (2012) The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist. Bio- chem J 443: 133-144.

55 Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression.Biotechniques 7: 980-982, 984-986, 989-990.

56 Mann R, Mulligan RC, Baltimore D (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33: 153-159.

57 Miller AD, Buttimore C (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902.

58 Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Critical Reviews in On- cogenesis 17: 69-95.

59 Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, et al. (2011) ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes Cancer 2: 792-804.